China Drug Makers Explore AI Marketing During Anti-Graft Scrutiny – Unite.AI

Reuters reported on November 11, 2026 that pharmaceutical companies in China are exploring marketing through artificial intelligence medical assistants and disease-specific personalized academic platforms as stricter anti-corruption enforcement complicates traditional visits to doctors and hospitals.

Opportunities fall into two distinct categories. Gu Fei, CEO of Null Hypothesis, said major Chinese and foreign drugmakers have licensed its KnowS product to build doctor-facing academic platforms focused on particular diseases, though he declined to name them. Other ideas remain mooted: Alibaba Health is considering placing promoted research and clinical evidence alongside relevant AI-generated answers on Hydrion, while drugmakers have discussed the importance of research and academic approvals with Yidu Tech, which does not yet offer such features on Yidu Evidence.

Alibaba Health has not initiated collaborations with drugmakers on Hydrion, although chief technology officer Wang Xiangzhi described interest from domestic and foreign companies as strong. Roche said it was exploring third-party medical AI tools for direct marketing to doctors and hospitals, while Bayer said it was monitoring technology that could support compliant engagement with healthcare providers.

Gu described a shift away from hospitality and gift exchange toward tools that support clinical work and research. Medically, he said, “this really gives me a new ability and helps me improve efficiency, rather than giving me two bottles of Moutai.”

Compliance pressure meets the growing use of artificial intelligence

A multi-year campaign against bribery and corruption in the healthcare sector intensified in the summer of 2026, when authorities introduced tougher measures for pharmaceutical employees who provide product information to doctors and hospitals. Medlive’s interim findings from August 28, 2026 describe sustained enforcement and physician representation rules as increasing compliance requirements, with drugmakers reducing spending on traditional promotion and increasing the share of budgets for digital academic marketing built around traceable clinical evidence.

Alibaba Health’s survey of hundreds of doctors found that 93% were using artificial intelligence tools, up from about 70% a year earlier. The comparison points to rapid adoption among clinicians, but measures AI tools broadly rather than the use of a single platform.

Frost & Sullivan estimates that Chinese enterprise spending on digital healthcare marketing will grow at a compound annual rate of 27.5% from 2027 to 2030, reaching RMB 274.4 billion. Its projection covers the broadest category and does not provide separate data for AI applications aimed at doctors.

Testing tools provide the distribution channel

Alibaba Health’s Hydrion product page describes literature and guideline searches, drug information search, AI question answering, PDF translation and summarization, and content collaborations with BMJ, JAMA, and NEJM. The resources listed include 40 million documents, more than 30,000 guidelines, and more than 60,000 drug instructions.

JD Health’s Zhiyi report from September 8, 2026 states that the assistant launched in January 2026 and has served more than one million physicians and supported more than 20 million clinical decision-making interactions. Its evidence locator feature identifies the original text supporting a clinical point, allowing clinicians to trace the generated information back to the underlying evidence.

JD Health formed its PICA Health partnership in August 2026, making Zhiyi available free of charge to registered GPs via the PICA app. PICA Health says the AI-embedded content is limited to disease education, clinical guidelines and standards of care, excludes branded drug recommendations and product-oriented content, and is subject to academic review. This policy draws a line between clinical training and brand-oriented promotion on the PICA platform, even as pharmaceutical companies seek access to the same medical workflow.

The business grows faster than revenue

Medlive’s interim results show 217 precision marketing and enterprise solutions healthcare customers in the first half of 2026, up from 191 a year earlier, while marketed products increased from 445 to 509. Segment revenue increased 1.1% to RMB295.5 million.

The company attributed the gap between business expansion and modest revenue growth to two pressures: Tighter regulation has disrupted doctors’ participation in online and offline academic activities and delayed some projects, while smaller pharmaceutical marketing budgets have limited short-term investments in digital academic marketing.

For now, the KnowS license and Medlive’s customer growth show that parts of the change are already commercial, while the trials advertised alongside AI responses and preferred search placement remain proposed. The opportunity is tied to a question of compliance: how platforms distinguish doctor education and trackable clinical trials from brand-directed promotion as drugmakers seek a broader presence in doctors’ daily workflows.